
    
      RETHINC is a 12-week multicenter, randomized, double-blind, placebo-controlled,
      parallel-group study to assess the efficacy and safety of indacaterol/glycopyrrolate
      27.5/15.6 mcg inhaled twice daily in symptomatic current and former smokers with respiratory
      symptoms despite preserved spirometry as defined by CAT ≥ 10 and post-bronchodilator FEV1/FVC
      ratio ≥0.70, respectively.
    
  